SK34296A3 - Assembled particles of plant virus, manufacture process and a vaccine on their base, a fragment of cdna, a vector containing this fragment and their rna transcripts - Google Patents
Assembled particles of plant virus, manufacture process and a vaccine on their base, a fragment of cdna, a vector containing this fragment and their rna transcripts Download PDFInfo
- Publication number
- SK34296A3 SK34296A3 SK342-96A SK34296A SK34296A3 SK 34296 A3 SK34296 A3 SK 34296A3 SK 34296 A SK34296 A SK 34296A SK 34296 A3 SK34296 A3 SK 34296A3
- Authority
- SK
- Slovakia
- Prior art keywords
- virus
- plant virus
- assembled
- plant
- sequence
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 119
- 239000002245 particle Substances 0.000 title claims abstract description 64
- 238000000034 method Methods 0.000 title claims abstract description 22
- 229960005486 vaccine Drugs 0.000 title claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 4
- 239000012634 fragment Substances 0.000 title claims description 11
- 239000013598 vector Substances 0.000 title claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 62
- 101710132601 Capsid protein Proteins 0.000 claims abstract description 17
- 101710094648 Coat protein Proteins 0.000 claims abstract description 16
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims abstract description 16
- 101710125418 Major capsid protein Proteins 0.000 claims abstract description 16
- 101710141454 Nucleoprotein Proteins 0.000 claims abstract description 16
- 101710083689 Probable capsid protein Proteins 0.000 claims abstract description 16
- 241000196324 Embryophyta Species 0.000 claims description 101
- 241000723655 Cowpea mosaic virus Species 0.000 claims description 56
- 239000002773 nucleotide Substances 0.000 claims description 35
- 125000003729 nucleotide group Chemical group 0.000 claims description 35
- 108091034117 Oligonucleotide Proteins 0.000 claims description 32
- 108090000565 Capsid Proteins Proteins 0.000 claims description 29
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 28
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 25
- 230000003612 virological effect Effects 0.000 claims description 24
- 239000002299 complementary DNA Substances 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 15
- 108091008146 restriction endonucleases Proteins 0.000 claims description 15
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 241000430519 Human rhinovirus sp. Species 0.000 claims description 9
- 241000701489 Cauliflower mosaic virus Species 0.000 claims description 8
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 230000007017 scission Effects 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 210000001938 protoplast Anatomy 0.000 claims description 6
- 241001493065 dsRNA viruses Species 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 239000000813 peptide hormone Substances 0.000 claims description 4
- 108700012941 GNRH1 Proteins 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 241000701931 Canine parvovirus Species 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 229960004854 viral vaccine Drugs 0.000 claims description 2
- 241000723607 Comovirus Species 0.000 claims 2
- 244000037640 animal pathogen Species 0.000 claims 2
- 239000011246 composite particle Substances 0.000 claims 1
- 230000001143 conditioned effect Effects 0.000 claims 1
- 244000052637 human pathogen Species 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000003508 trans-4-hydroxy-L-proline group Chemical group 0.000 claims 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 40
- 150000001413 amino acids Chemical class 0.000 description 27
- 238000006386 neutralization reaction Methods 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000010276 construction Methods 0.000 description 13
- 241000710122 Rhinovirus B14 Species 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 230000003472 neutralizing effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000003902 lesion Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 101100135798 Caenorhabditis elegans pcp-1 gene Proteins 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101100135809 Mus musculus Pcp2 gene Proteins 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108020005089 Plant RNA Proteins 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 108010066124 Protein S Proteins 0.000 description 2
- 102000029301 Protein S Human genes 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 101800000874 Small capsid protein Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 244000042314 Vigna unguiculata Species 0.000 description 2
- 235000010722 Vigna unguiculata Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010915 one-step procedure Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 206010020164 HIV infection CDC Group III Diseases 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000710124 Human rhinovirus A2 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 102000036072 fibronectin binding proteins Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8202—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector
- C12N15/8203—Virus mediated transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9414118A GB9414118D0 (en) | 1994-07-13 | 1994-07-13 | Modified plant viruses as vectors of heterologous peptides |
PCT/GB1995/001618 WO1996002649A1 (en) | 1994-07-13 | 1995-07-10 | Modified plant viruses as vectors of heterologous peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
SK34296A3 true SK34296A3 (en) | 1996-07-03 |
Family
ID=10758254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK342-96A SK34296A3 (en) | 1994-07-13 | 1995-07-10 | Assembled particles of plant virus, manufacture process and a vaccine on their base, a fragment of cdna, a vector containing this fragment and their rna transcripts |
Country Status (16)
Country | Link |
---|---|
US (1) | US5958422A (de) |
EP (1) | EP0719336B1 (de) |
JP (1) | JP3681753B2 (de) |
KR (1) | KR100379803B1 (de) |
CN (1) | CN1211488C (de) |
AT (1) | ATE346934T1 (de) |
AU (1) | AU697867B2 (de) |
BR (1) | BR9506047A (de) |
CA (1) | CA2170412C (de) |
CZ (1) | CZ290484B6 (de) |
DE (1) | DE69535314T2 (de) |
GB (1) | GB9414118D0 (de) |
HU (1) | HU223078B1 (de) |
NZ (1) | NZ289170A (de) |
SK (1) | SK34296A3 (de) |
WO (1) | WO1996002649A1 (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6846968B1 (en) | 1988-02-26 | 2005-01-25 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
US6660500B2 (en) | 1988-02-26 | 2003-12-09 | Large Scale Biology Corporation | Production of peptides in plants as viral coat protein fusions |
US7033835B1 (en) | 1988-02-26 | 2006-04-25 | Large Scale Biology Corporation | Production of peptides in plants as viral coat protein fusions |
US5977438A (en) * | 1988-02-26 | 1999-11-02 | Biosource Technologies, Inc. | Production of peptides in plants as viral coat protein fusions |
GB9108386D0 (en) * | 1991-04-19 | 1991-06-05 | Agricultural Genetics Co | Modified plant viruses as vectors |
US5612487A (en) * | 1991-08-26 | 1997-03-18 | Edible Vaccines, Inc. | Anti-viral vaccines expressed in plants |
US6034298A (en) * | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
US5484719A (en) | 1991-08-26 | 1996-01-16 | Edible Vaccines, Inc. | Vaccines produced and administered through edible plants |
AU6976296A (en) * | 1995-09-15 | 1997-04-01 | John A Howard | Expression cassettes and methods for delivery of animal vaccines |
GB9712282D0 (en) * | 1997-06-12 | 1997-08-13 | Innes John Centre Innov Ltd | Epitope presentation system |
US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
GB9921337D0 (en) | 1999-09-09 | 1999-11-10 | Axis Genetics Plc | Modified plant viruses |
GB9924351D0 (en) | 1999-10-14 | 1999-12-15 | Brennan Frank | Immunomodulation methods and compositions |
US7135282B1 (en) | 1999-10-14 | 2006-11-14 | The Dow Chemical Company | Viral particles with exogenous internal epitopes |
WO2001098335A2 (en) * | 2000-06-20 | 2001-12-27 | Phycotransgenics, Llc | Transgenic algae for delivering antigens to an animal |
US6932980B1 (en) * | 2001-01-18 | 2005-08-23 | Richard Sayre | Method of making microalgal-based animal foodstuff supplements, microalgal-supplemented animal foodstuffs and method of animal nutrition |
IL151882A0 (en) * | 2001-01-24 | 2003-04-10 | Virogene Ltd | Vectors capable of imparting herbicide resistance and viral cross protection |
MXPA05000287A (es) * | 2002-07-05 | 2005-09-08 | Leclerc Denis | Particula viral adyuvante. |
US8101189B2 (en) * | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
EP1720990A4 (de) * | 2004-02-27 | 2008-04-30 | Dow Global Technologies Inc | Hocheffiziente peptidproduktion in pflanzenzellen |
WO2006124044A2 (en) * | 2004-07-30 | 2006-11-23 | George Mason University | Protein scaffolds and viral particles for detecting analytes |
US20060216238A1 (en) * | 2005-02-28 | 2006-09-28 | Marianne Manchester | Compositions and methods for targeting or imaging a tissue in a vertebrate subject |
EP1885394A4 (de) * | 2005-06-01 | 2009-10-21 | Dow Global Technologies Inc | Herstellung multivalenter, virusartiger partikeln |
CN101227920A (zh) * | 2005-07-19 | 2008-07-23 | 陶氏环球技术公司 | 重组流感疫苗 |
JP2010508860A (ja) * | 2006-11-15 | 2010-03-25 | フォリア バイオテック インコーポレイテッド | パパイヤモザイクウイルスに基づくインフルエンザ用ワクチン |
DE602007003944D1 (de) * | 2007-01-03 | 2010-02-04 | Academia Sinica | Rekombinante virale Proteine und Partikel |
CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
DK2610345T3 (en) | 2007-11-27 | 2015-12-07 | Medicago Inc | RECOMBINANT INFLUENZA VIRUS SIMULAR PARTICULARS (VLPS) MADE IN TRANSGENE PLANTS THAT EXPRESS HEMAGGLUTININ |
CN102165062B (zh) | 2008-07-18 | 2017-09-08 | 麦迪卡格公司 | 新的流感病毒免疫表位 |
WO2010012069A1 (en) * | 2008-07-30 | 2010-02-04 | Folio Biotech Inc. | Multivalent vaccines based on papaya mosaic virus and uses thereof |
US20100183523A1 (en) | 2009-01-22 | 2010-07-22 | Wagner Richard E | Dental composition and method |
WO2010148511A1 (en) | 2009-06-24 | 2010-12-29 | Medicago, Inc. | Chimeric influenza virus-like particles comprising hemagglutinin |
SG178947A1 (en) | 2009-09-22 | 2012-04-27 | Medicago Inc | Method of preparing plant-derived proteins |
ES2625406T3 (es) | 2010-03-25 | 2017-07-19 | Oregon Health & Science University | Glicoproteínas de CMV y vectores recombinantes |
SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2679596B1 (de) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 Env-proteinvariante |
EP2848937A1 (de) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Verfahren zur Identifizierung neuartiger HIV-1-Immunogene |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CN105980561B (zh) | 2014-01-10 | 2020-06-02 | 莫迪卡戈公司 | Cpmv增强子元件 |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US10617751B2 (en) | 2017-07-13 | 2020-04-14 | VisionTech International Limited | Edible vaccines expressed in yeast for preventing and treating infectious diseases in animals and humans |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8421282D0 (en) * | 1984-08-22 | 1984-09-26 | Connaught Lab | Multispecific antigenic proteins |
AU638411B2 (en) * | 1988-02-26 | 1993-07-01 | Large Scale Biology Corporation | Non-nuclear chromosomal transformation |
WO1991013994A1 (en) * | 1990-03-13 | 1991-09-19 | Commonwealth Scientific And Industrial Research Organisation | Gene expression |
EP0527767A4 (en) * | 1990-04-06 | 1993-05-05 | Commonwealth Scientific And Industrial Research Organisation | Self-polymerising expression system based on modified potyvirus coat proteins |
WO1993003161A1 (en) * | 1990-10-22 | 1993-02-18 | Biosource Genetics Corporation | Recombinant plant viral nucleic acids |
GB9108386D0 (en) * | 1991-04-19 | 1991-06-05 | Agricultural Genetics Co | Modified plant viruses as vectors |
AU1838495A (en) * | 1994-02-03 | 1995-08-21 | Scripps Research Institute, The | Method for using tobacco mosaic virus to overproduce peptides and proteins |
-
1994
- 1994-07-13 GB GB9414118A patent/GB9414118D0/en active Pending
-
1995
- 1995-07-10 HU HU9600586A patent/HU223078B1/hu not_active IP Right Cessation
- 1995-07-10 WO PCT/GB1995/001618 patent/WO1996002649A1/en active IP Right Grant
- 1995-07-10 CA CA002170412A patent/CA2170412C/en not_active Expired - Fee Related
- 1995-07-10 DE DE69535314T patent/DE69535314T2/de not_active Expired - Lifetime
- 1995-07-10 SK SK342-96A patent/SK34296A3/sk unknown
- 1995-07-10 JP JP50478996A patent/JP3681753B2/ja not_active Expired - Fee Related
- 1995-07-10 US US08/612,858 patent/US5958422A/en not_active Expired - Fee Related
- 1995-07-10 CN CNB951907956A patent/CN1211488C/zh not_active Expired - Fee Related
- 1995-07-10 AT AT95924436T patent/ATE346934T1/de not_active IP Right Cessation
- 1995-07-10 NZ NZ289170A patent/NZ289170A/en not_active IP Right Cessation
- 1995-07-10 KR KR1019960701197A patent/KR100379803B1/ko not_active IP Right Cessation
- 1995-07-10 EP EP95924436A patent/EP0719336B1/de not_active Expired - Lifetime
- 1995-07-10 CZ CZ1996723A patent/CZ290484B6/cs not_active IP Right Cessation
- 1995-07-10 BR BR9506047A patent/BR9506047A/pt not_active Application Discontinuation
- 1995-07-10 AU AU28934/95A patent/AU697867B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
US5958422A (en) | 1999-09-28 |
CZ72396A3 (en) | 1996-06-12 |
AU697867B2 (en) | 1998-10-22 |
DE69535314T2 (de) | 2007-03-08 |
CA2170412A1 (en) | 1996-02-01 |
CN1211488C (zh) | 2005-07-20 |
HU223078B1 (hu) | 2004-03-29 |
EP0719336A1 (de) | 1996-07-03 |
HUP9600586D0 (en) | 1996-05-28 |
HUT75088A (en) | 1997-04-28 |
WO1996002649A1 (en) | 1996-02-01 |
DE69535314D1 (de) | 2007-01-11 |
AU2893495A (en) | 1996-02-16 |
NZ289170A (en) | 1997-11-24 |
EP0719336B1 (de) | 2006-11-29 |
GB9414118D0 (en) | 1994-08-31 |
JP3681753B2 (ja) | 2005-08-10 |
JPH09504961A (ja) | 1997-05-20 |
BR9506047A (pt) | 1997-08-05 |
KR100379803B1 (ko) | 2003-10-04 |
CZ290484B6 (cs) | 2002-08-14 |
ATE346934T1 (de) | 2006-12-15 |
CN1134174A (zh) | 1996-10-23 |
CA2170412C (en) | 2010-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK34296A3 (en) | Assembled particles of plant virus, manufacture process and a vaccine on their base, a fragment of cdna, a vector containing this fragment and their rna transcripts | |
US6884623B1 (en) | Modified plant viruses as vectors of heterologous peptides | |
Porta et al. | Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides | |
Turpen et al. | Malaria epitopes expressed on the surface of recombinant tobacco mosaic virus | |
US5916563A (en) | Parvovirus protein presenting capsids | |
US5534257A (en) | Antigen-presenting capsid with fusion MS2-coat protein | |
CN105555958A (zh) | 水疱性口炎病毒的改性基质蛋白 | |
DK169276B1 (da) | Vaccine indeholdende et immunogent virusprotein | |
US20030186431A1 (en) | Rabbit hemorrhagic disease vaccine and antigens | |
WO1998056933A1 (en) | Polypeptide presentation system | |
WO1992014489A1 (en) | Poliovirus-based vaccines | |
EP0475987A1 (de) | Impfstoff gegen hiv | |
MXPA99011361A (en) | Dna sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same |